270 related articles for article (PubMed ID: 24799129)
1. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells.
Redmer T; Welte Y; Behrens D; Fichtner I; Przybilla D; Wruck W; Yaspo ML; Lehrach H; Schäfer R; Regenbrecht CR
PLoS One; 2014; 9(5):e92596. PubMed ID: 24799129
[TBL] [Abstract][Full Text] [Related]
2. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.
Civenni G; Walter A; Kobert N; Mihic-Probst D; Zipser M; Belloni B; Seifert B; Moch H; Dummer R; van den Broek M; Sommer L
Cancer Res; 2011 Apr; 71(8):3098-109. PubMed ID: 21393506
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
4. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
Boyle SE; Fedele CG; Corbin V; Wybacz E; Szeto P; Lewin J; Young RJ; Wong A; Fuller R; Spillane J; Speakman D; Donahoe S; Pohl M; Gyorki D; Henderson MA; Johnstone RW; Papenfuss AT; Shackleton M
Cancer Res; 2016 Jul; 76(13):3965-77. PubMed ID: 27325642
[TBL] [Abstract][Full Text] [Related]
5. CD271 is an imperfect marker for melanoma initiating cells.
Cheli Y; Bonnazi VF; Jacquel A; Allegra M; De Donatis GM; Bahadoran P; Bertolotto C; Ballotti R
Oncotarget; 2014 Jul; 5(14):5272-83. PubMed ID: 25105565
[TBL] [Abstract][Full Text] [Related]
6. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.
Boiko AD; Razorenova OV; van de Rijn M; Swetter SM; Johnson DL; Ly DP; Butler PD; Yang GP; Joshua B; Kaplan MJ; Longaker MT; Weissman IL
Nature; 2010 Jul; 466(7302):133-7. PubMed ID: 20596026
[TBL] [Abstract][Full Text] [Related]
7. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
Lai CY; Schwartz BE; Hsu MY
Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
[TBL] [Abstract][Full Text] [Related]
8. CD271 determines migratory properties of melanoma cells.
Radke J; Roßner F; Redmer T
Sci Rep; 2017 Aug; 7(1):9834. PubMed ID: 28852061
[TBL] [Abstract][Full Text] [Related]
9. Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures.
Valyi-Nagy K; Kormos B; Ali M; Shukla D; Valyi-Nagy T
Mol Vis; 2012; 18():588-92. PubMed ID: 22419851
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity.
Li S; Yue D; Chen X; Wang L; Li J; Ping Y; Gao Q; Wang D; Zhang T; Li F; Yang L; Huang L; Zhang Y
Oncol Rep; 2015 Jan; 33(1):425-32. PubMed ID: 25351876
[TBL] [Abstract][Full Text] [Related]
11. Identification of melanoma initiating cells: does CD271 have a future?
Ballotti R
Future Oncol; 2015; 11(11):1587-90. PubMed ID: 26043212
[No Abstract] [Full Text] [Related]
12. CD271 defines a stem cell-like population in hypopharyngeal cancer.
Imai T; Tamai K; Oizumi S; Oyama K; Yamaguchi K; Sato I; Satoh K; Matsuura K; Saijo S; Sugamura K; Tanaka N
PLoS One; 2013; 8(4):e62002. PubMed ID: 23626764
[TBL] [Abstract][Full Text] [Related]
13. Bmi-1 is essential for the oncogenic potential in CD133(+) human laryngeal cancer cells.
Wei X; He J; Wang J; Yang X; Ma B
Tumour Biol; 2015 Nov; 36(11):8931-42. PubMed ID: 26081615
[TBL] [Abstract][Full Text] [Related]
14. Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.
Panaccione A; Guo Y; Yarbrough WG; Ivanov SV
Clin Breast Cancer; 2017 Jul; 17(4):298-306.e7. PubMed ID: 28216417
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
[TBL] [Abstract][Full Text] [Related]
16. Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells.
Morita S; Mochizuki M; Wada K; Shibuya R; Nakamura M; Yamaguchi K; Yamazaki T; Imai T; Asada Y; Matsuura K; Sugamura K; Katori Y; Satoh K; Tamai K
Cancer Lett; 2019 Oct; 461():144-152. PubMed ID: 31325530
[TBL] [Abstract][Full Text] [Related]
17. CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.
Feng BH; Liu AG; Gu WG; Deng L; Cheng XG; Tong TJ; Zhang HZ
Oncol Rep; 2013 Aug; 30(2):815-23. PubMed ID: 23708735
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
19. Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells.
Yu B; Wang Y; Yu X; Zhang H; Zhu J; Wang C; Chen F; Liu C; Wang J; Zhu H
Int J Nanomedicine; 2017; 12():2553-2567. PubMed ID: 28435246
[TBL] [Abstract][Full Text] [Related]
20. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
